Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
US-12059448-B2 · Aug 13, 2024 · US
Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
US11040083B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11040083-B2 |
| Application number | US-201615764621-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2016 |
| Priority date | Sep 29, 2015 |
| Publication date | Jun 22, 2021 |
| Grant date | Jun 22, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are polypeptides including at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising the three following vinculin binding sites (VBS): VBS1: IYKAAKDVTTSLSKVLKNI (SEQ ID NO: 2) or a variant thereof, wherein the variant of SEQ ID NO: 2 is a polypeptide having a sequence identity of at least 90% with SEQ ID NO: 2; VBS2: IYEKAKEVSSALSKVLSKI (SEQ ID NO: 3) or a variant thereof, wherein the variant of SEQ ID NO: 3 is a polypeptide having a sequence identity of at least 90% with SEQ ID NO: 3; and VBS3: IFEASKKVTNSLSNLISLI (SEQ ID NO: 4) or a variant thereof, wherein the variant of SEQ ID NO: 4 is a polypeptide having a sequence identity of at least 90% with SEQ ID NO: 4; wherein said polypeptide consists of 140 to 160 amino acids and wherein said polypeptide is not cytotoxic upon cell transfection as compared to the full-length invasion plasmid antigen A (IpaA) protein of SEQ ID NO:1. 2. The polypeptide according to claim 1 , wherein said polypeptide is SEQ ID NO: 5 or a variant thereof, wherein the variant of SEQ ID NO: 5 is a polypeptide having a sequence identity of at least 90% with SEQ ID NO: 5.
Assignees
Inventors
Classifications
- A61K38/06Primary
Tripeptides · CPC title
specific for metastasis · CPC title
Shigella (G) · CPC title
characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11040083B2 cover?
- Disclosed are polypeptides including at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.
- Who is the assignee on this patent?
- Paris Sciences Et Lettres—Quartier Latin, Centre Nat Rech Scient, Inst Nat Sante Rech Med, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).